passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
Company profile
Ticker
PASG
Exchange
Website
CEO
Bruce Goldsmith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
822729751
PASG stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
S-8
Registration of securities for employees
4 Mar 24
S-3
Shelf registration
4 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
4 Mar 24
8-K
Other Events
29 Feb 24
8-K
Regulation FD Disclosure
5 Jan 24
Transcripts
PASG
Earnings call transcript
2022 Q4
6 Mar 23
PASG
Earnings call transcript
2022 Q3
10 Nov 22
PASG
Earnings call transcript
2022 Q2
6 Aug 22
PASG
Earnings call transcript
2022 Q1
16 May 22
PASG
Earnings call transcript
2021 Q4
3 Mar 22
PASG
Earnings call transcript
2021 Q3
6 Nov 21
PASG
Earnings call transcript
2021 Q3
4 Nov 21
PASG
Earnings call transcript
2021 Q2
8 Aug 21
PASG
Earnings call transcript
2021 Q2
5 Aug 21
PASG
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
SC 13D/A
ORBIMED ADVISORS LLC
12 Apr 24
SC 13G
Lynx1 Capital Management LP
29 Mar 24
4
Kathleen Borthwick
19 Mar 24
4
Mark S Forman
19 Mar 24
4
William Chou
19 Mar 24
4
Edgar B. Cale
19 Mar 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
4
Kathleen Borthwick
13 Feb 24
4
Mark S Forman
13 Feb 24
4
Mark S Forman
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm |
Cash burn (monthly) | (no burn) | 2.42 mm | 9.56 mm | 9.85 mm | 6.39 mm | 6.90 mm |
Cash used (since last report) | n/a | 16.58 mm | 65.59 mm | 67.59 mm | 43.83 mm | 47.33 mm |
Cash remaining | n/a | 17.00 mm | -32.01 mm | -34.01 mm | -10.26 mm | -13.75 mm |
Runway (months of cash) | n/a | 7.0 | -3.3 | -3.5 | -1.6 | -2.0 |
Institutional ownership, Q2 2023
75.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 9 |
Closed positions | 11 |
Increased positions | 8 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 27.70 bn |
Total shares | 46.57 mm |
Total puts | 0.00 |
Total calls | 1.70 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 10.12 mm | $9.53 bn |
Versant Venture Management | 4.96 mm | $4.67 bn |
Versant Venture Capital VI | 4.03 mm | $80.53 mm |
Access Industries | 2.62 mm | $16.62 mm |
Frazier Life Sciences IX | 2.54 mm | $2.38 mm |
New Leaf Ventures III | 2.50 mm | $63.87 mm |
New Leaf Venture Partners, L.L.C. | 2.50 mm | $2.35 bn |
LAV Prescience | 2.20 mm | $13.97 mm |
BML Capital Management | 2.06 mm | $1.94 bn |
Vanguard | 2.02 mm | $1.90 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Kathleen Borthwick | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 227,000 | 340.50 k | 227,000 |
15 Mar 24 | Mark S Forman | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 203,000 | 304.50 k | 203,000 |
15 Mar 24 | William Chou | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 575,000 | 862.50 k | 575,000 |
15 Mar 24 | Edgar B. Cale | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 203,000 | 304.50 k | 203,000 |
13 Feb 24 | Kathleen Borthwick | Common Stock | Sell | Dispose S | No | No | 0 | 1,470 | 0.00 | 28,466 |
10 Feb 24 | Kathleen Borthwick | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,000 | 0.00 | 29,936 |
10 Feb 24 | Kathleen Borthwick | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,000 | 0.00 | 8,000 |